GUZI, Timothy, Kamil PARUCH, Michael DWYER, Marc LABROLI and Kartik KEERTIKAR. Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors. 2007.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
Name in Czech Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
Authors GUZI, Timothy, Kamil PARUCH, Michael DWYER, Marc LABROLI and Kartik KEERTIKAR.
Edition Number: US 2007/00772881 A1, Publisher: United States Patent and Trademark Office, Place of publication: USA, Owner's name: Schering-Plough, 2007.
Other information
Original language English
Type of outcome Patent
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Organization unit Faculty of Science
Keywords (in Czech) pyrazolopyrimidine; cyclin dependent kinase; inhibitor
Keywords in English pyrazolopyrimidine; cyclin dependent kinase; inhibitor
Tags Cyclin dependent kinase, inhibitor, pyrazolopyrimidine
Changed by Changed by: doc. Mgr. Kamil Paruch, Ph.D., učo 108413. Changed: 25/6/2009 15:03.
Abstract
Title compds. I [R = H, alkyl, alkenyl, etc.; R2 = H, CF3, alkyl, heterocyclyl, etc.; R3 = H, halo, OH, SH, alkyl, etc.; R4 = H, halo or alkyl], and their pharmaceutically acceptable salts, are prepd. and disclosed as inhibitors of cyclin dependent kinases (CDKs). Thus, e.g., II was prepd. by amination of III (prepn. given) followed by deprotection. Methods for in vitro kinase assays are described, e.g., II was found to possess an IC50 value of 10 (.mu.M). Further disclosed are pharmaceutical compns. contg. one or more of I, methods of prepg. pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with the CDKs using such compds. or pharmaceutical compns.
Abstract (in Czech)
viz Anotace
PrintDisplayed: 2/8/2024 23:23